According to Zacks, “Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. While more traditional oncology drug discovery approaches attempt to generate antibodies against known targets, Atrecas approach relies on the human immune system to direct it to unique antibody-target pairs from patients experiencing a clinically meaningful, active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets. “
A number of other research analysts have also issued reports on the stock. Roth Capital assumed coverage on shares of Atreca in a research note on Wednesday, September 4th. They set a buy rating and a $30.00 price target on the stock. Cowen reiterated a buy rating on shares of Atreca in a research report on Wednesday, August 14th. Finally, Brookline Capital Management reissued a buy rating on shares of Atreca in a report on Tuesday, August 20th. Seven equities research analysts have rated the stock with a buy rating, Atreca currently has a consensus rating of Buy and an average price target of $22.53.
Shares of NASDAQ BCEL traded down $0.23 during mid-day trading on Tuesday, hitting $14.24. 229,277 shares of the company were exchanged, compared to its average volume of 106,544. The business’s 50 day moving average is $10.93. Atreca has a 1-year low of $9.51 and a 1-year high of $23.65.
Atreca (NASDAQ:BCEL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.09. On average, research analysts expect that Atreca will post -4.09 EPS for the current year.
Several hedge funds have recently made changes to their positions in the company. Millennium Management LLC boosted its position in shares of Atreca by 117.7% in the third quarter. Millennium Management LLC now owns 57,649 shares of the company’s stock worth $705,000 after acquiring an additional 31,174 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of Atreca in the 3rd quarter valued at $234,000. Barclays PLC boosted its holdings in shares of Atreca by 261.6% in the 3rd quarter. Barclays PLC now owns 5,063 shares of the company’s stock valued at $62,000 after purchasing an additional 3,663 shares during the last quarter. California State Teachers Retirement System acquired a new position in shares of Atreca in the 3rd quarter valued at $124,000. Finally, State Street Corp purchased a new stake in shares of Atreca during the 3rd quarter valued at $1,056,000. Institutional investors and hedge funds own 57.76% of the company’s stock.
Atreca Company Profile
Atreca, Inc, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Featured Article: How is a Moving Average Calculated?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.